[Cyclooxygenases inhibitors and other compounds with antiinflammatory potential in osteoarthrosis--part II].
NO-NSAIDs (or CINODs that is COX-inhibiting nitric oxide donors) are new class of antiinflammatory drugs and have a multi-pathway mechanism of action that involves cyclooxygenases (COXs) inhibition and nitric oxide (NO) donation. The first drug of this group is naproxcinod, which exerts rarely adverse effects of stomach, gut and less cardiovascular toxicity with naproxen. NO is an important mediator of endothelial function acting as a vasodilator and plays role in inflammation and pain perception that may be of relevance in osteoarthritis and in healing injures in stomach and gut. Lipoxins (LX, LXs): LXA4, LXB4 are group of lipid mediators leading to resolution of inflammation and protective influence on gastrointestinal mucosa. ATL (AT mean aspirin triggered therefore "depend on aspirin") synthesis, via COX-2, reduces the severity of damage gastrointestinal tract induced by NSAIDs. ATL also plays role in gastric adaptation during chronic aspirin administration. Antiinflammatory drugs hydrogen sulfide-releasing (H2S) (ATB-337 that consist of diclofenac linked to a hydrogen sulfide-releasing moiety) may show better efficacy and less toxicity. COX/5-LOX inhibitors and NO-NSAIDs heals symptoms of osteoarthrosis.